|
C20ORF30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.58055815499847E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.36362098968857E-13 |
| Normal-vs-Stage2 |
6.227800E-02 |
| Normal-vs-Stage3 |
1.98789873451233E-11 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
7.181500E-03 |
| Stage1-vs-Stage3 |
1.184590E-01 |
| Stage1-vs-Stage4 |
8.12000000000035E-05 |
| Stage2-vs-Stage3 |
1.215900E-03 |
| Stage2-vs-Stage4 |
1.78419999999901E-05 |
| Stage3-vs-Stage4 |
6.002100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.76445533131664E-14 |
| Normal-vs-AfricanAmerican |
1.77039999993411E-07 |
| Normal-vs-Asian |
1.03909999493723E-08 |
| Caucasian-vs-AfricanAmerican |
2.695000E-01 |
| Caucasian-vs-Asian |
4.038200E-01 |
| AfricanAmerican-vs-Asian |
2.173800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.4226000044637E-08 |
| Normal-vs-Female |
3.30790950187065E-12 |
| Male-vs-Female |
2.339000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.63211674678132E-12 |
| Normal-vs-Age(41-60Yrs) |
2.8264002249756E-10 |
| Normal-vs-Age(61-80Yrs) |
1.23149999975425E-07 |
| Normal-vs-Age(81-100Yrs) |
2.718400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.632600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.917600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.408800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.166800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.067000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.764800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.122300E-03 |
| Classical-VS-Follicular |
4.45439999996466E-07 |
| Classical-VS-Other |
2.327600E-01 |
| Classical-VS-Normal |
1.62525548574877E-12 |
| Tall-VS-Follicular |
1.10380005136079E-09 |
| Tall-VS-Other |
8.870300E-02 |
| Tall-VS-Normal |
1.17683640610267E-14 |
| Follicular-VS-Other |
9.937400E-01 |
| Follicular-VS-Normal |
1.813540E-02 |
| Other-VS-Normal |
4.584000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.87080000380035E-08 |
| Normal-vs-N1 |
1.15241149956091E-13 |
| N0-vs-N1 |
5.030300E-04 |
|
|
